A phase III trial of thymosin beta-4 in patients with epidermolysis bullosa

Trial Profile

A phase III trial of thymosin beta-4 in patients with epidermolysis bullosa

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Thymosin-beta-4 (Primary)
  • Indications Epidermolysis bullosa
  • Focus Therapeutic Use
  • Sponsors RegeneRx - G-treeBNT (JV)
  • Most Recent Events

    • 01 Mar 2017 New trial record
    • 27 Feb 2017 According to a RegeneRx Biopharmaceuticals media release, the US FDA has granted permission to conduct this trial and the company plans to initiate the trial during the third quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top